share_log

Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $26

Benzinga ·  Apr 30 08:02

Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $36 to $26.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment